Ken Griffin
BIOS

Ken Griffin’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Ken Griffin’s Portfolio BIOS Stock Details BIOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-88,240
Closed -$871K – 14533
2022
Q1 		$871K Buy
+88,240
New +$871K ﹤0.01% 8018

Other funds holding BIOS

SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return

Ken Griffin's BIOS Position: Q2 2022 in Review

Ken Griffin sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q2 2022, closing a stake of 88,240 shares — an estimated $871K sold.

Ken Griffin first reported a position in BIOS in Q1 2022 and held it in 1 quarter. The position peaked at $871K in Q1 2022. 65 funds tracked by Wall St. Rank hold BIOS as of Q2 2022.

  • Ken Griffin reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q2 2022 after selling out during the quarter.
  • Ken Griffin sold 88,240 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q2 2022, an estimated $871K.
  • Ken Griffin first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 1 quarter.
  • Ken Griffin's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $871K in Q1 2022.
  • 65 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.